Akari Therapeutics Plc - ADR
AKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.48M
Close$
$5.29
45.3% downside
Current Fair Value
45.3% downsideOvervalued by 45.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.48 Million |
|---|---|
| Enterprise Value | $3.48 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20800 |
| Beta | 1.43 |
| Outstanding Shares | 1,791,468 |
Return
| Return on Equity | -166.70% |
|---|---|
| Return on Assets | -80.26% |
| Return on Invested Capital | -128.09% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.97 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 4, 2026
EPS Estimate
$-2.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 10,000▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.37%▲ 8.28% |
|---|---|
| Total Invested | $1.54M▲ 399.83% |
| Investors Holding | 10▲ 4.00% |
ESG Score
No data
About Akari Therapeutics Plc
CEO: David Solomon